Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects
Clinical Pharmacology in Drug Development · 2023
DOI: 10.1002/cpdd.1310 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von HyunJoon Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Empagliflozin and metformin are oral antidiabetic drugs commonly used to treat type 2 diabetes mellitus as a combination therapy. This study aimed to compare the pharmacokinetics and safety of a newly developed fixed‐dose combination of 5‐mg empagliflozin L‐proline and 1000‐mg metformin with the reference drug. A randomized, open‐label, single‐dose, 2‐period, 2‐treatment, crossover study was conducted in healthy Korean subjects. The subjects received a single oral dose of reference drug or test drug at each period. The pharmacokinetic (PK) parameters were calculated using a noncompartmental method. The geometric mean ratios and 90% confidence intervals of the plasma maximum concentration (C max ) and area under the concentration–time curve from time zero to the last quantifiable concentration (AUC last ) were calculated. A total of 27 healthy subjects were included in the PK analysis. For empagliflozin, the geometric mean ratios (90% confidence intervals) of the test to reference drug for C max and AUC last were 1.03 (0.99–1.08) and 1.03 (1.00–1.06), respectively. For metformin, the corresponding values for C max and AUC last were 0.99 (0.92–1.06) and 1.00 (0.94–1.06), respectively. In conclusion, a fixed‐dose combination of empagliflozin L‐proline and metformin showed similar PK characteristics to the reference drug, and both drugs were safe in healthy subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
- Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Department of Pharmaceutical Research Laboratory, Chong Kun Dang Research Institute, Chong Kun Dan Pharmaceutical Corporation, Seoul, South Korea.
- Kidney Research Institute, Seoul National University Medical Research Center, Seoul, Republic of Korea.
Zitieren
APA
Lee, H., Chung, J. Y., Yu, K. S., Park, S. J., & Lee, S. (2023). Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1310
Vancouver
Lee H, Chung JY, Yu KS, Park SJ, Lee S. Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1310
BibTeX
@article{Lee2023,
author = {Lee, HyunJoon and Chung, Jae-Yong and Yu, Kyung-Sang and Park, Shin-Jung and Lee, Soyoung},
title = {Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
doi = {10.1002/cpdd.1310}
}
EUVIMED